Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569966 | 0.84 | KCNH2 (0.75) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL694568 | 0.80 | KCNH2 (0.53) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL1711764 | 0.80 | KCNH2 (0.53) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL864107 | 0.80 | KCNH2 (0.53) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL22315216 | 0.79 | KCNH2 (0.66) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL22314699 | 0.79 | MRGPRX4 (0.58) | KCNH2MRGPRX4LMNASMN1; SMN2NPC1 | |
| SCHEMBL1712277 | 0.78 | KCNH2 (0.50) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL863712 | 0.78 | KCNH2 (0.50) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 | |
| SCHEMBL22315218 | 0.76 | NPC1 (0.49) | KCNH2MRGPRX4LMNASMN1; SMN2NPC1 | |
| SCHEMBL22315194 | 0.75 | KCNH2 (0.56) | KCNH2MRGPRX4LMNACYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | claimed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | claimed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | claimed |
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | disclosed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | disclosed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2345328-A1 | COMPOSITION FOR AGRICULTURAL USE | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | H1-0, H1-3, H1-2 | KCNH2 669/4885MRGPRX4 2764/4885LMNA 3681/4885 |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | KCNH2 672/4885MRGPRX4 1885/4885LMNA 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.